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- Maintenance therapy with novel agents prolonged remission duration in both transplant-
ineligible and transplant-eligible patients with MM.  
- The appropriate maintenance strategy should be not only effective but also well tolerated. 
- In transplant-ineligible patients, single-agent thalidomide or lenalidomide showed positive 
results after thalidomide- and lenalidomide-based induction therapies, respectively. Bortezomib in 
association with thalidomide is also a valid strategy. 
- In transplant-eligible patients, single agent thalidomide resulted in improved PFS but was 
not well tolerated and in high risk cytogenetic patients may lead to inferior survival whereas 
bortezomib as part of induction and maintenance improves PFS in all patients and OS in patients 
with the del 17 cytogenetic abnormality and those who present in renal failure. 
- In transplant eligible patients, single agent lenalidomide is effective demonstrated improved 











Multiple myeloma (MM) is a neoplasm typical of the elderly, with median age at diagnosis of 70 
years, and approximately 65% of patients older than 65 years.1  Many advances have been made 
thanks to the use of autologous hematopoietic stem cell transplantation (AHSCT) and the 
introduction of the immunomodulatory drugs and the proteasome inhibitors. Incorporation of novel 
agents into induction has resulted in improved overall survival (OS) over the past decade2,3.  
Indeed, in a large group of 2981 patients with newly diagnosed MM, overall survival significant 
improved from 29.9 to 44.8 months in patients diagnosed in the last decade (P<0.001).3 The 
agents that have most impacted on progression-free survival (PFS) and OS are thalidomide4,5, 
lenalidomide6,7 and bortezomib.8-11 The alkylating agent cyclophosphamide in combination with 
bortezomib and dexamethasone generated comparable deep responses to bortezomib, 
lenalidomide and dexamethasone in a Phase II study.12  These combination induction regimens 
improve the overall response and the depth of response by increasing the percentage of patients 
achieving complete responses (CR).  Many MM patients will have disease progression or relapse 
and die of MM within 10 years of the initiation of therapy.  Thus, there is a pressing need for 
improved induction regimens and for strategies to control disease with the long term goal of cure. 
Of note, sequential approaches consisting of induction followed by consolidation and maintenance 
with novel agents have been recently tested with the attempt of improving the clinical benefit of 
current treatments.13 Consolidation improves responses after induction therapy (and 
transplantation when applicable) and maintenance further delays relapse/progression with the 
ultimate goal of improving OS. Consolidation consists of two to four cycles of combination 
therapies and maintenance of continuous therapy, usually with single agents, until disease 
progression.14 Maintenance therapy is suggested for both transplant-ineligible patients (usually 
elderly patients over 65 years) and transplant-eligible ones (patients younger than 65 years of age). 
However, no specific guidelines are available, and the optimal duration of maintenance remains to 
be established.15  
Optimal MM maintenance therapy should maintain or increase response after induction and, when 
possible, AHSCT.  Maintenance therapy should be easily given (preferably oral) and if 
administered intravenously, convenient for the patient.  Due to the lack of long term efficacy and 
tolerability, agents such as melphalan, interferon-α and glucocorticoids have not become widely 
used for maintenance16-19.  Newer agents are more attractive as maintenance therapies due to 
improved efficacy and better tolerability.  The majority of maintenance studies have used 
thalidomide and more recently, bortezomib and lenalidomide. Different studies have assessed the 
benefits associated with maintenance treatment incorporating thalidomide, lenalidomide and 
bortezomib, yet no clinical study has directly compared the advantages of one approach over the 
other. Despite the benefits associated with continuous novel-agent-based therapy, prolonged 
exposure to new drugs may increase toxicities and cause treatment discontinuation. Therefore the 




Maintenance approaches for patients ineligible for transplantation 
Patients over 65 years of age do not tolerate intensive therapy and are usually ineligible for high-
dose melphalan (MEL200; melphalan 200 mg/m2) and AHSCT). For these patients gentler 
strategies should be used. Combinations with novel agents, such as thalidomide, lenalidomide and 
bortezomib, are widely adopted, both for newly diagnosed and relapse patients with MM. In the 
1970s, maintenance treatment for this subset of patients consisted of prolonging chemotherapy 
after successful induction treatment with melphalan-prednisone (MP).21-23 Other attempts of 
maintenance therapies consisted of using single-agent interferon.24,25  
 
Thalidomide 
Thalidomide can be a suitable option for prolonged use because of the oral administration. 
Nevertheless, the neurological toxicity associated with this drug is a major concern and should be 
carefully considered. To date, continuous thalidomide after melphalan-prednisone-thalidomide 
(MPT) induction has been evaluated in four of the trials (Table 1).5,26-29 In one study, 100 mg/day 
thalidomide was given continuously. The median progression-free survival (PFS) was 25 months 
for patients who received thalidomide and 15 months for those who did not (P<0.001). The median 
OS was 48 months and 45 months for the two arms, respectively (P=0.79).5,26 The incidence of 
grade 3-4 neurological toxicity was 10% in patients receiving thalidomide therapy and 1% in those 
receiving no maintenance. In another study, thalidomide was administered at 200 mg/ day at 
induction and was reduced to 50 mg/day during maintenance. The median event-free survival 
(EFS) time was 13 months for patients who received thalidomide and 9 months for those who did 
not (P<0.001). A marginally statistically significant OS advantage favoring thalidomide 
maintenance was also detected, with a median of 40 months versus 31 months (P=0.05).27 The 
incidence of grade 3-4 neurologic toxicities was particularly higher with thalidomide (23%) than no 
thalidomide (4%). In another study, thalidomide at the dose of 200 mg/day was administered 
continuously until relapse.28 The median PFS (15 months versus 14 months, P=0.84) and OS (29 
months versus 32 months, P=0.16) was similar between patients who received thalidomide and 
those who did not. The incidence of grade 3-4 peripheral neuropathy was quite low in both arms, 
6% versus 1%, respectively. These findings support the concept that thalidomide maintenance 
should be administered at the minimal effective dose associated with the lowest toxicity (50 to 100 
mg/day) in order avoid early discontinuation. 
Another randomized trial assessed the role of thalidomide-interferon or interferon alone as 
maintenance therapy after induction with either thalidomide-dexamethasone (TD) or MP.30 The 
median PFS was 28 months for patients who received thalidomide maintenance and 13 months for 
those who received interferon alone (P=0.007). The median OS was similar in the two groups (53 
months versus 51 months, P=0.81). The rate of grade 3-4 neuropathy was 7% versus 0%, 
respectively (P=0.002). Finally, in another study, a total of 820 patients, both eligible and ineligible 
for AHSCT, were randomized to thalidomide maintenance or no maintenance. Patients ineligible 
for AHSCT had received melphalan-prednisone or cyclophosphamide-thalidomide-dexamethasone 
induction.31 In these patients, thalidomide maintenance improved PFS (23 versus 15 months, 
P<0.001), and the advantage was more evident in patients who had received thalidomide also at 
induction. The median OS was not significantly different between the two arms (P=0.40). In 
patients with adverse iFISH, thalidomide maintenance had a negative impact on OS (P=0.009).  
All the studies including thalidomide maintenance reported an improvement in terms of PFS, 
although longer follow-up is needed to detect an OS benefit. The risk of peripheral neuropathy after 
long-term thalidomide exposure is a major limitation to its routine use. To avoid excessive 
neurologic toxicity and consequently treatment discontinuation, the preferred dose of thalidomide 
maintenance should range between 50 and 100 mg/day.32 In case of occurrence of grade 3-4 
neurotoxicity it is highly recommended to temporarily interrupt treatment until resolution to at least 




Lenalidomide, similarly to thalidomide, is administered orally and has the additional advantage of 
lower neurologic toxicity.  
A phase 3 study evaluated the role of lenalidomide at 10 mg on days 1-21 of each 28-day cycle 
after melphalan-prednisone-lenalidomide (MPR-R) versus MPR versus MP.33 The median PFS 
was 31 months with MPR-R, 14 months with MPR and 13 months  with MP. In a landmark analysis 
from start of lenalidomide maintenance, lenalidomide after MPR significantly prolonged the median 
PFS from 7 to 26 months (P<0.001). No particular advantage was seen in terms of OS, and the 4-
year OS was approximately 58% in the three treatment groups. One of the major toxicity 
associated with lenalidomide is neutropenia, which was reported in 7% of patients in the MPR-R 
arm. Some concerns about the increased risk of second primary malignancies (SPM) with 
prolonged exposure to lenalidomide were raised. In this study, the rate of SPM was 7% for both 
MPR-R and MPR, and 3% for MP. Nevertheless, the benefits associated with lenalidomide 
treatment outweigh the increased risk of SPM. A recent meta-analysis on 3218 patients found that 
patients treated with lenalidomide had an increased risk of developing hematological SPM (HR 
1.55; p=0.037). Of note, the risk was increased when lenalidomide was given with melphalan 
compared with melphalan alone (HR 4.86; p<0.0001), while exposure to lenalidomide plus 
cyclophosphamide (HR 1.26; p=0.75) or lenalidomide plus dexamethasone (HR 0.86; p=0.76) did 
not increase haematological SPM risk versus melphalan alone. Thus the use of alternative 
alkylating agents can be a possible option.34 
A phase 2 study evaluated a sequential approach consisting of lenalidomide-prednisone (RP) 
induction followed by MPR consolidation and subsequent RP maintenance (lenalidomide 10 
mg/day on days 1-21 of each 28-day cycle; prednisone 25 mg three times/week).35 Median age 
was 75 years, 59% of patients had at least one comorbidity and 35% at least two. Median PFS was 
18.4 months and 2-year OS was 80%. Grade 4 neutropenia occurred in 12% of patients. Therefore, 
this study demonstrated that the addition of prednisone increases the efficacy of lenalidomide 
alone in unfit elderly MM patients, with the advantage of a low toxicity and consequently improved 
quality of life.  
A recent large phase 3 study compared lenalidomide plus low dose dexamethasone (Rd) until 
relapse versus Rd for 18 cycles (72 weeks) versus MPT for 12 cycles (72 weeks).36 Median age 
was 73 years. After a median follow-up of 37 months, Rd significantly improved PFS compared 
with MPT (HR 0.72; p=0.00006) and marginally OS (HR 0.78, p=0.01685). Relevant grade 3-4 
adverse events with Rd until relapse versus MPT were neutropenia (28% versus 45%), 
thrombocytopenia (8% versus 11%), febrile neutropenia (1% versus 3%), infection (29% versus 
17%), neuropathy (5% versus 15%), and deep-vein thrombosis (5% versus 3%). The respective 
incidence of hematologic SPM was 0.4% versus 2.2%; the overall incidence of solid tumors was 
identical (2.8%). These results suggest the need for prolonging therapy until progression, since 
outcome after 18 cycles of therapy was similar between Rd and MPT.  Continuous Rd is therefore 
a valid option in transplant-ineligible patients, and may be preferred to the standard MPT with no 
maintenance.  
Although elderly patients are usually not able to tolerate MEL200 and AHSCT, reduced intensity 
transplantation with melphalan 100 mg/m2 (MEL100) can be safely adopted for fit elderly patients. 
A phase 2 study assessed bortezomib-adriamicyn-dexamethasone (PAD) induction followed by 
tandem MEL100, AHSCT, lenalidomide-prednisone consolidation and lenalidomide maintenance in 
patients aged 65 to 75 years.37 This approach induced a median PFS of 48 months and a 5-year 
OS of 63%. Consolidation and maintenance with lenalidomide considerably increased responses, 
mostly in subjects who had achieved a very good partial response after transplantation. During 
consolidation and maintenance, the main toxicities were hematological; in particular, neutropenia 
(19% after consolidation and 23% after maintenance) and thrombocytopenia (15% after 
consolidation and 3% after maintenance).  
Based on the data available, lenalidomide seems to be the most suitable choice for maintenance 





Bortezomib is another possible option as maintenance therapy. Peripheral neuropathy associated 
with this drug may be a limitation, yet its incidence is lower than that reported with thalidomide.  
In one study, bortezomib plus either thalidomide (VT) or prednisone (VP) was given after induction 
with either VMP or bortezomib-thalidomide-prednisone (VTP).38 The median PFS was longer with 
VT (32 months) than VP (24 months), yet this difference was not statistically significant (P=0.1). No 
OS advantage favoring one of the two options was detected, and the incidence of peripheral 
neuropathy was slightly higher with VT (7%) than VP (2%). 
In another study, bortezomib-melphalan-prednisone-thalidomide (VMPT) induction followed by VT 
maintenance (VMPT-VT) was compared with VMP followed by no maintenance.39 VT consisted of 
bortezomib at 1.3 mg/m2 every 15 days and thalidomide at 50 mg per day for 2 years or until 
progression or relapse. The median PFS was significantly longer with VMPT-VT (35.3 months) 
than with VMP (24.8 months; HR 0.58; P<0.001). The 5-year OS was greater with VMPT-VT (61%) 
than with VMP (51%; HR 0.70; P=0.01). Of note, the use of once-weekly bortezomib instead of 
twice-weekly administration appeared to be an appropriate strategy to improve tolerability and 
decrease discontinuation.40 During the maintenance phase with VT, the incidence of new or 
worsened grade 3-4 toxicities was low (less than 5%). Grade 3-4 neutropenia was reported in four 
patients (3%), peripheral neuropathy in six patients (4%), and cardiologic adverse events in two 
patients (1%).  
Another study assessed the role of bortezomib alone as maintenance therapy (1.6 mg/m2, d 1, 8, 
15, 22 for five 35-day cycles) after induction with bortezomib-dexamethasone (VD), bortezomib-
thalidomide-dexamethasone (VTD), or VMP.41 The median PFS was 14.7 months with VD, 15.4 
months with VTD, and 17.3 months with VMP. The respective median OS was 49.8, 51.5, and 53.1 
months. Grade 3-4 adverse events were lower with VD (78%) than VTD (87%) and VMP (83%). 
Bortezomib maintenance was associated with limited additional toxicity compared with induction.  
A recent study evaluated the role of a sequential strategy with VMP followed by Rd versus the 
same regimens in an alternating approach. A total of 18 cycles was planned for both approaches.42 
After a median follow-up of 12 months, the 18-month time-to-progression was 83% with the 
sequential strategy and 89% with the alternating approach. A trend in favour of the alternating 
approach was seen in patients with high-risk cytogenetics profile (84% versus 94%). The 
respective 18-month OS was 83% and 93%. Yet, the difference between the two options was not 
statistically significant. Hematologic toxicities were lower in the sequential strategy (neutropenia: 
16% versus 23%; thrombocytopenia: 16% versus 20%). Non-hematologic toxicities were low, with 
infections being the most common (5% versus 4% respectively). Both the sequential and the 
alternating approaches proved to be feasible and well tolerated.  
In conclusion, bortezomib induces a lower rate of peripheral neuropathy than thalidomide, and 
maintenance with bortezomib plus thalidomide is effective and safe in patients ineligible for 
MEL200 and AHSCT. The lack of SPM and the possibility of the subcutaneous administration 
make bortezomib an advantageous strategy for maintenance. Although combining two agents 
associated with a potential risk of neurotoxicity can be a concern, the use of reduced dose 
intensities makes VT a valid maintenance option. Alternating VMP and Rd is an appealing option, 
particularly in high-risk patients, but further investigation is needed. 
 
Maintenance approaches for patients eligible for transplantation 
The paradigm in 2014 for transplant-eligible patients consists of induction, stem cell mobilization, 
AHSCT followed by consolidation and/or maintenance43,44.  Recent studies have demonstrated 
improved outcomes in transplant-eligible patients receiving maintenance therapy and new 
approaches to consolidation and maintenance are currently being investigated for transplant 
eligible patients.  This portion of the review focuses on maintenance therapy following AHSCT for 
transplant-eligible MM patients.   
 
Thalidomide  
The maintenance thalidomide studies resulted in improved EFS or PFS with OS that were 
improved, no different from maintenance or worse for selected high risk patients (Table 2). Four 
Phase III studies studied thalidomide maintenance until progression32,45-48. (Table 2) The 
Intergroupe Francophone du Myelome (IFM) randomized 400 patients after AHSCT to thalidomide 
versus no maintenance and demonstrated an improved 3-year EFS (52% versus 37%, P<0.009) 
and an improved 4 year OS (87% versus 75%, P<0.04)32.  A United States of America (USA) 
single institution study from the Arkansas group demonstrated a significant benefit for thalidomide 
versus no thalidomide maintenance.  The 5-year EFS was 64% for thalidomide and 43 % for no 
maintenance (P<0.001) and the 8 year OS was 57% for thalidomide versus 44% for no 
maintenance (P=0.09)45. A Stichting Hemato-Oncologie voor Volwassensen Nederland (Dutch-
Belgian Cooperative Trial Group for Hematology Oncology) (HOVON) compared thalidomide and 
interferon-α maintenance and demonstrated that thalidomide improved the median EFS (34 versus 
22 months, P<0.001) and resulted in a non-significant increase in median OS (73 versus 60 
months, P=0.77)46.  The Medical Research Council of the United Kingdom (MRC UK) Myeloma IX 
study examined intensive (transplant) and non-intensive (non-transplant) approaches for the 
treatment of newly diagnosed MM patients.  For the transplant arm, thalidomide maintenance 
resulted in a median PFS of 22 months versus 15 months for the no maintenance arm (P<0.0001).  
The median OS was 60 months in both groups (P=0.70)47,48.  The median PFS benefit due to 
thalidomide maintenance was seen only in the patients with low risk cytogenetics analyses at 
diagnosis (29 versus 18 months, P=0.01) but without OS benefit.  For patients with high risk 
cytogenetic analyses, the OS was inferior for patients receiving thalidomide maintenance when 
compared to no maintenance (35 versus 47 months, P=0.01). 
There have been four studies that have examined thalidomide plus glucocorticoids as maintenance 
after AHSCT49-52.  An Australian study compared 243 patients receiving one year of thalidomide 
with prednisolone until progression to patients receiving prednisolone alone until progression49.  
The 3-year PFS for the thalidomide/prednisolone arm 42% and 23% for prednisolone only arm 
(P<0.001).  The 3-year OS for the thalidomide/prednisolone arm was 86% and 75% for the 
prednisolone only arm (P=0.004).  A USA trial, BMT-CTN 0102 compared AHSCT followed by 
reduced-intensity allogeneic HSCT with tandem AHSCT as the primary objective50.  Patients were 
assessed as low or high risk based on clinical and cytogenetic features.  The tandem AHSCT 
patients received Thalidomide and dexamethasone maintenance or observation alone.  Following 
the first AHSCT, the 3-year PFS for low (standard) risk MM patients randomized to thalidomide and 
dexamethasone was 49% and 43% in the observation arm (P=0.08).  There was no difference in 
the 3-year OS: 80% for the thalidomide and dexamethasone arm and 81% for the observation 
group (P=0.82).  A Brazilian study studied 108 MM patients receiving single AHSCT by 
randomizing them to 12 months of either thalidomide and dexamethasone or dexamethasone 
alone maintenance51.  The 2-year PFS was 64% for the thalidomide and dexamethasone arm and 
30% for the dexamethasone only arm (P=0.002).  There was no difference in the 2 year OS: 85% 
for the thalidomide and dexamethasone arm and 70% for the dexamethasone alone arm (P=0.27).  
The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Eastern 
Cooperative Oncology Group (ECOG) maintenance study randomized 332 MM patients receiving a 
single AHSCT to thalidomide and prednisone versus observation after AHSCT52.  The PFS for 
thalidomide-prednisone was superior to observation: (4-year estimates: 32% vs. 14%; HR=0.56; 
P<0.0001). At 4 years median follow-up, the OS was 68% for thalidomide and prednisone and 60% 
for observation (P=0.18).  Lower or standard risk MM patients benefited the most from 
maintenance therapy.  Prolonged maintenance was not tolerated by a significant proportion of 
patients in all of the thalidomide studies.   
 
Zoledronate  
Zoledronate was compared to clodronate as supportive care during induction and maintenance 
therapy for MM patient receiving intensive (including AHSCT) and non-intensive (non-AHSCT) 
therapy for the initial treatment48,53.  The primary maintenance question was the use of thalidomide 
therapy until progression with a secondary objective asking if every 3 to 4 week zoledronate 
therapy until progression would result in less skeletal related events than daily oral clodronate. In 
the early report, for AHSCT patients, the median OS was not reached for the zoledronate arm and 
was 62 months for clodronate arm. (HR 0.84, 95% CI, 0.68–1.03; P=0.0854).  When combining 
both intensive and non-intensively treated patients, the median PFS was significantly longer in 
patients randomized to zoledronate when compared to patients randomized to clodronate (19 
versus 18 months; HR 0.89; 95% CI, 0.80–0.98; P=0.02).  The median OS was significantly longer 
for patients receiving zoledronate (52 versus 46 months; HR, 0.86; 95% CI, 0.77–0.97; P=0.01.  
There were more incidence of osteonecrosis of the jaw (ONJ) with zoledronate versus clodronate 
(3.7% versus 0.5%; P<0.0001) and most ONJ events were considered low-grade.  These results 
imply that zoledronate may have an anti-MM effect as has been previously described54.  Recent 
recommendations for bisphosphonate therapy were monthly for a year than change to every 3 
months in year two then stop55.  The early recognition and management of ONJ, the superiority of 
long term use of zoledronate over pamidronate for decreasing skeletal-related events56 and the 
MRC IX trial results give consideration for zoledronate therapy until progression or at a minimum 
the continuation of zoledronate with active disease and resumption at disease progression48. 
 
Lenalidomide  
There are two Phase III studies that have examined lenalidomide maintenance therapy after 
AHSCT57,58.  A third study has reported preliminary results examining lenalidomide maintenance 
after chemotherapy or AHSCT59.  A fourth study has examined lenalidomide alone versus 
lenalidomide plus prednisone after chemotherapy or AHSCT60.  The studies are compared in Table 
3.   
The CALGB 100104 study randomized 462 newly diagnosed MM patients who had received 
various induction regimens to lenalidomide 10 mg daily (dose range 5 to 15 mg) versus placebo 
until progression after single AHSCT57.  Of the induction regimens, 74% contained either 
thalidomide-or lenalidomide in combination with other agents. There was no pre- or post-AHSCT 
consolidation. The median time to progression (TTP) was 46 months for the lenalidomide arm and 
27 months for the placebo arm (P<0.001).  The 3 year PFS was 66% for the lenalidomide arm and 
39% for the placebo arm (P<0.001).  With a median follow-up of 34 months the 3-year OS rate for 
the lenalidomide arm was 88% and 80% for the placebo arm (P=0.028). The primary endpoint of 
TTP was met early and the study was un-blinded 22 months prior to this analysis when 86 of 128 
eligible (non-progressing) placebo arm patients crossed over and began lenalidomide.  Despite the 
cross-over, there has been a persistent TTP and OS benefit for the lenalidomide arm.  An updated 
analysis was performed in 2013 at a median follow-up of 48 months, the OS was 80% for the 
lenalidomide group and 70% for the placebo group (P=0.008)61.  A PFS advantage persisted for 
the lenalidomide arm.  Patients receiving lenalidomide had an increased incidence of hematologic 
toxicities (neutropenia and thrombocytopenia) as well as an increase in SPM. There were 
8/231(3.5%) hematologic malignancies, primarily myeloid malignancies (Acute Myeloid 
Leukemia/Myelodysplastic Syndrome (AML/MDS) n=6) on the lenalidomide arm and 1/229 (0.4%), 
Non-Hodgkin Lymphoma (NHL) n=1 on the placebo arm.  There were 10/231 (4.3%) versus 5 
(2.1%) solid tumors on the lenalidomide and 4/231 (1.7%) on the placebo arm.  The SPM 
cumulative incidence risk was greater for the lenalidomide arm (P<0.008).  The cumulative 
incidence risks of progressive disease (P<0.001) or death (P<0.002) were greater for the placebo 
arm.  When counting events as progressions, deaths and SPMs, the median EFS was 43 months 
for the lenalidomide arm and 27 months for the placebo arm (P<0.001).   
The IFM 05-02 study examined 605 patients randomized to lenalidomide at the same dose range 
as CALGB 100104 versus placebo until progression after single (79%) or two AHSCT (21%). After 
the first or second AHSCT, all patients received a 2 cycle consolidation treatment of 25 mg of 
lenalidomide for three weeks out of four at approximately day 60 to 120 days post-AHSCT.  
Induction regimens consisted of vincristine, doxorubicin and dexamethasone (VAD) or VD.  
Twenty-five percent of patients received pre-AHSCT consolidation with dexamethasone, 
cyclophosphamide, etoposide and cisplatin (DCEP).  The median PFS was 41 months for the 
lenalidomide arm patients and 23 months for the placebo arm patients (P<0.001).  At 4 years, the 
PFS was 43% for the lenalidomide arm patients and 22% for the placebo arm patients (P<0.001).  
At a 45 month median follow-up, the OS was 74% for the lenalidomide arm and 76% for the 
placebo arm.  The 4-year OS rates were 73% for the lenalidomide arm and 75% for the placebo 
arm (P=0.7).  The study was also un-blinded 22 months prior to analysis.  All maintenance was 
stopped at a median time of 2 years (range 1-3 years).  There was no cross over for the placebo 
arm patients.  This study was updated recently62.  Now, with a median follow up of 60 months from 
randomization, the lenalidomide arm had an improved PFS (42%) compared to the placebo arm 
(18%) (P<0.0001).  At 5 years, the OS for the lenalidomide arm is 68% and 67% for the placebo 
arm (HR=1).  After first progression, the median survival is 29 months for the lenalidomide arm and 
48 months for the placebo arm (P<0.0001).  There was an increased incidence of hematologic 
toxicities (primarily neutropenia and thrombocytopenia) and increased incidence of SPMs in the 
lenalidomide arm.  There were 13/306(4.2%) hematologic malignancies primarily lymphoid 
malignancies (acute lymphocytic leukemia (ALL) and Hodgkin lymphoma (HL) n=7, for 
lenalidomide arm patients and 5/302 (1.6%) primarily AML/MDS n=4, for the placebo arm patients.  
For solid tumors, there were 10/306 (3.3%) in lenalidomide arm patients and 4/302 (1.3%) in 
placebo arm patients.  The median EFS (including progressions, deaths and SPMs) was 40 
months for the lenalidomide arm and 23 months for the placebo arm (P<0.001).   
The third lenalidomide maintenance study following chemotherapy (melphalan, prednisone, 
lenalidomide) versus tandem AHSCT with high-dose melphalan (MPR versus MEL200) has been 
reported59.  Both chemotherapy and tandem AHSCT maintenance patients were combined and 
compared to those chemotherapy and tandem AHSCT patients who did not receive lenalidomide 
maintenance.  At 49 months median follow-up, from chemotherapy or tandem AHSCT and at 35 
months median follow-up from randomization to lenalidomide maintenance or no maintenance, the 
3-year PFS for the lenalidomide maintenance patients was 37 months and 26 months for patients 
not receiving maintenance (P<0.0001). Five-year OS estimates were 75% for the lenalidomide arm 
and 58% for the no maintenance arm (P=0.02). The rate of SPMs was 4.5% in both maintenance 
arms (chemotherapy and tandem AHSCT). Another GIMEMA study examined maintenance 
therapy with lenalidomide plus prednisone versus lenalidomide alone following chemotherapy 
(cyclophosphamide, lenalidomide, prednisone) versus tandem AHSCT (CRD versus MEL200) in 
389 newly diagnosed MM patients60. The chemotherapy and tandem AHSCT patients randomized 
to receive lenalidomide/prednisone maintenance were combined and compared to the 
chemotherapy and tandem AHSCT patients who were randomized to receive lenalidomide alone.  
At 31 months median follow-up from chemotherapy or tandem AHSCT, the 3-year PFS for 
lenalidomide/prednisone arm was 60% and 38% for lenalidomide alone (P=0.003).  There was no 
difference in 3-year OS. 
A meta-analysis of IFM 05 02, CALGB 100104, MPR vs Mel200 and MM 01533 (a non-transplant 
trial) found that lenalidomide maintenance when compared to placebo improves PFS with a trend 
to an OS benefit63.  Table 4 compares the differences between CALGB 100104 and IFM 05-02 
which may help to explain the differences in OS, and types of SPM. In particular, there are 
differences in induction regimens, number of transplants, use of consolidation pre and post AHSCT 
and length of maintenance therapy. 
The SPM etiologic risk factors are not fully defined.  MM and monoclonal gammopathy of unknown 
significance (MGUS) have been associated with the development of AML/MDS64.  In this registry 
study, MGUS patients would have not received therapy implying that there is an undefined stem 
cell defect in MGUS patients and by inference MM patients (who have the addition risk of 
chemotherapy exposure) predisposing to the development of myeloid malignancies.  A recent 
meta-analysis of 7 randomized controlled trials of more than 3000 newly diagnosed MM patients 
found that those who received lenalidomide had an increased risk of developing hematological 
SPMs, driven mainly by treatment strategies that included a combination of lenalidomide and oral 
melphalan34.  Lenalidomide treatment with intravenous melphalan and other agents did not carry 
as high a risk as oral melphalan for the development of SPMs.  Furthermore, with lenalidomide 
therapy, the risk of dying from MM or treatment-related adverse events remained higher than the 
risk of death due to SPMs.  The HOVON-65/GMMG-HD4 two-year bortezomib maintenance was 
not associated with an increase in SPM65.  The risk of SPM needs to be factored and balanced 
against the beneficial effects on PFS and OS when patients and clinicians decide on the use of 
maintenance treatment.  So far there is no OS benefit with is seen with the recent IFM 05-02 
analysis.  Future and ongoing studies should facilitate the understanding of the optimal 
maintenance strategies for long term control of MM.    
The IFM 05-02, MRC UK Medical Research Council United Kingdom IX, PETHEMA, HOVON 65 
GMMG HD4 studies used induction regimens that are being superseded by novel agent 
combinations.  The CALGB 100104 study contained patients who received older thalidomide-
based induction regimens in addition to lenalidomide-containing regimens. Thus, we need to 
evaluate these studies relative to the induction regimens in use today.  New studies incorporating 
newer agents, in particular bortezomib and lenalidomide are underway and are described later in 
this review.  Unlike induction regimens, the standard AHSCT conditioning regimens remains high 
dose melphalan alone or in combination with agents such as bortezomib. 
MM patients receiving induction therapy followed by consolidation with high dose melphalan and 
AHSCT often will have disease progression and relapse.  Therefore, maintaining disease response 
is an important goal for MM management after AHSCT.  Depth of response as manifested by the 
presence or absence of minimal residual disease correlates with long term disease control66,67.  
However factors such as disease staging, cytogenetics, and gene expression profiling predict long 
term outcome68.  Thus, there have been attempts to incorporate cytogenetic risk factors and 
minimal residual disease detection69.  Determining the most effective combination of induction, 
transplant dose intensive therapy, consolidation and maintenance will be accomplished with a goal 
of improved survival endpoints, patient tolerance and patient quality-of-life.   
AHSCT is a standard approach to the management of transplant-eligible MM patients after 
induction therapy.  The superiority of AHSCT over prolonged lower dose therapy has been 
demonstrated before use of bortezomib and lenalidomide in induction therapy70,71.  A recent phase 
III study has shown a superior PFS and OS for early tandem transplant versus continued lower 
dose therapy.  There are recently completed and ongoing phase III studies that examine the utility 
of upfront versus delayed AHSCT, the role of consolidation and single versus tandem AHSCT and 
the use of maintenance therapy72-75.  The recently completed STAMINA trial (Stem cell transplant 
with lenalidomide maintenance in patients with multiple myeloma), BMT-CTN 0702 compared 
single, tandem AHSCT and single AHSCT followed by lenalidomide, bortezomib and 
dexamethasone consolidation72.  Induction regimens were at the discretion of the enrolling centers.  
Originally all three arms were to be followed by lenalidomide maintenance for 3 years.  The 
protocol has been amended to extend maintenance until progression.  The European Myeloma 
Network (EMN) trial, Study to Compare VMP With HDM Followed by VRD Consolidation and 
Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma  EMN 2 (HO95) 
will treat all NDMM patients with an induction regimen of bortezomib, cyclophosphamide and 
dexamethasone.  Patients are randomized to three arms: bortezomib, melphalan, prednisone 
therapy, single or tandem AHSCT.  After completion of this segment of the protocol, patients will 
either receive no consolidation versus consolidation with lenalidomide, bortezomib and 
dexamethasone before all patients receive lenalidomide maintenance until progression73.  The 
Dana Farber Cancer Institute (DFCI 10-106) (IFM DFCI 2009) randomized trial compares 8 cycles 
of lenalidomide, bortezomib and dexamethasone, cyclophosphamide mobilization of hematopoietic 
stem cells and AHSCT at relapse with 3 cycles of lenalidomide, bortezomib and dexamethasone, 
cyclophosphamide mobilization of hematopoietic stem cells and upfront AHSCT followed by 2 
cycles of lenalidomide, bortezomib and dexamethasone consolidation74. The IFM will treat patients 
with one year of lenalidomide maintenance.  The study in the USA has been changed to 
maintenance lenalidomide until progression. The MRC myeloma XI trial, a randomised comparison 
of thalidomide and lenalidomide combinations in myeloma patients of all ages will enroll patients on 
either an intensive (transplant) pathway or a non-intensive (non-transplant) pathway75.  The 
intensive pathway compares two induction regimens and examines consolidation or no 
consolidation pre-AHSCT for patients with less than a VGPR.  After single AHSCT, patients will be 
randomized to no maintenance or lenalidomide maintenance until disease progression.   
 
Bortezomib  
Bortezomib, the first proteasome inhibitor approved for the treatment of MM has been studied as 
both part of induction and maintenance therapy. The HOVON-65/German-speaking-Myeloma 
Multicenter Group (GMMG)-HD4 randomized 827 symptomatic and newly diagnosed MM patients 
to either of two induction regimens: VAD or PAD65.  After induction all patients underwent stem cell 
mobilization with cyclophosphamide, doxorubicin and dexamethasone with granulocyte colony-
stimulating factor followed by stem cell collection.  Some high risk patients received eligible for 
allogeneic HSCT: VAD: 5% and PAD: 7%.  German patients underwent tandem AHSCT due to 
clinical practice.  The majority of patients VAD: (84%) and PAD patients: (85%) underwent single 
or tandem AHSCT followed by 2 years of maintenance.  The VAD arm received thalidomide and 
the PAD arm received bortezomib.  The study was first reported at a median follow-up of 41months.  
The median PFS for the PAD-P arm 35 months and for the VAD-T arm was 28 months (P=0.002) 
(Table 5).  The multivariate analysis established a HR for PAD-P of 0.77 (95% CI, 0.60 to 1.00, 
P=0.049.  Patients with the poor risk cytogenetic feature of del 17p13 receiving PAD-P had an 
improved median PFS (22 versus 12 months, (P=0.01)) and improved OS (not reached at 54 
months versus 24 months, (P=0.003)) when compared to VAD-T.  Patient in renal failure at 
diagnosis also had an improved PFS and OS when PAD-P when compared to VAD-T.  There was 
no difference in PFS and OS for other cytogenetic risk groups.  The Spanish Myeloma group, 
(Grupo Espanol de Mieloma (GEM) PETHEMA (Programa para el Estudio de la Terapéutica en 
Hemopatías Malignas) conducted a 386 patient trial that randomized newly diagnosed MM patients 
to 3 different induction treatments : VTD versus TD versus alternating chemotherapy: vincristine, 
carmustine, melphalan, cyclophosphamide, prednisone (VBMCP)/vincristine, carmustine, 
doxorubicin, dexamethasone (VBAD)76.  Following induction, all eligible patients received a single 
AHSCT.  All three induction groups were randomized to maintenance therapy for 3 years with 
interferon-α versus T or VT.  At a median follow-up of 2 years from maintenance initiation, the PFS 
for the VT maintenance treatment was significantly longer than T or interferon-α (78% versus 63% 




The introduction of novel agent-based maintenance therapy has considerably prolonged remission 
duration for MM patients. In transplant-ineligible patients, standard induction therapies consist of 
novel-agent based three-drug regimens. Two-drug regimens and gentler approaches with reduced 
doses are suggested in frail patients. The route of administration is fundamental while choosing 
maintenance therapy: thalidomide and lenalidomide have the advantage of the oral administration 
in comparison with intravenous bortezomib. Of note, in patients ineligible for transplantation, an OS 
benefit was reported with bortezomib maintenance while it was inconsistently detected with 
strategies including thalidomide and lenalidomide. The optimal maintenance approach should also 
be associated with a low toxicity to preserve quality of life. Peripheral neuropathy is a major 
concern with continuous thalidomide, less frequent with bortezomib, while it is less frequent with 
lenalidomide. Nevertheless, lenalidomide is associated with an increased risk of SPM. Future trials 
are needed to establish which option is the most suitable as maintenance therapy for transplant-
ineligible subjects, and head-to-head comparisons are therefore necessary. The optimal duration 
of treatment is another crucial point that needs further investigation. In conclusion, the data 
available show that a sequential approach including induction therapy followed by consolidation 
and maintenance therapy is an appropriate and effective strategy in MM. 
The current treatment standard for the transplant-eligible patient is induction therapy, preferably 
with 3 agents, including novel agents (proteasome inhibitor and or IMiD).  Induction treatment is 
given to best response with the goal of attainment of CR.  Trials in the USA and Europe will help 
define the optimal induction regimen, the role of single or tandem AHSCT or delayed AHSCT after 
salvage therapy at relapse.  Consolidation therapy following AHSCT is discussed in another 
chapter.  Following AHSCT with or without consolidation, maintenance therapy is becoming a 
standard approach to maintain response and control disease long term.  The optimal maintenance 
strategy will be defined with future studies. 
Understanding risk should allow for developing strategies for long term disease control based on 
diagnostic disease characteristics.  In addition to cytogenetic risk stratification, gene expression 
profiling (GEP) has been developed for defining high risk patients77,78.  However, the optimal 
treatment approach for these high risk patients has yet to be defined and these high risk patients 
should be evaluated for new approaches.  Novel drugs with novel mechanisms of action may offer 
strategies that could convert high risk disease into lower disease79.  Ongoing studies will answer 
questions regarding the incorporation of new agents into induction treatment, the role of early 
versus delayed AHSCT, the role of consolidation and standard approaches to maintenance 
therapy to prolong and control disease and improve outcome.   
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Table 1. Main maintenance approaches for patients ineligible for MEL200 and transplantation 
 
Drug Study Schedule Response  Median PFS/TTP/EFS Median OS Previous induction 
Palumbo et al.5,26 T: 100 mg/day until relapse 16% CR 22 months 45 months MPT 
Wijermans et al.27 T: 50 mg/day until relapse 23% ≥VGPR 13 months 40 months MPT 
Waage et al.28 T: 200 mg/day until progression 13% CR 15 months 29 months MPT 
Beksac et al.29 T: 100 mg/day until relapse 9% CR 21 months 26 months MPT 
Ludwig et al.30 
T: 200 mg/day until progression or 
intolerance; I: 3 Mega units three 
times a week 







Morgan et al.31 
T: 50 mg/day increased to 100 mg/day 
after four cycles (if tolerated) until 
progression 
--- 23 months --- MP or CTDa  
Palumbo et al.33 
R: 10 mg days 1-21 until disease 







Gay et al.37 
R: 25 mg days 1-21; P: 50 mg qod 










48 months 63% @ 60 months PAD-MEL100§ 
Mateos et al.38 
V: 1.3 mg/m2 twice weekly, on days 1, 
4, 8, 11, every 3 months; P: 50 mg 
qod for up to 3 years 
39% CR 32 months --- VMP or VTP 
Mateos et al. 38 
V: 1.3 mg/m2 twice weekly, on days 1, 
4, 8, 11, every 3 months; T: 50 mg/day 
for up to 3 years 








Palumbo et al. 39 
V: 1.3 mg/m2 every 14 days; T: 50 
mg/day for 2 years 
42% CR* 56% @ 36 months 61% @ 60 months VMPT 
 
T, thalidomide; I, interferon α-2b; R, lenalidomide; P, prednisone; V, bortezomib; MPT, melphalan-prednisone-thalidomide; MPR, melphalan-prednisone-lenalidomide; TD, thalidomide-dexamethasone; 
CTDa, cyclophosphamide-thalidomide-dexamethasone attenuated; PAD, bortezomib-doxorubicin-dexamethasone; MEL100, melphalan 100 mg/m2; VMP, bortezomib-melphalan-prednisone; VTP, 
bortezomib-thalidomide-prednisone; VMPT, bortezomib-melphalan-prednisone-thalidomide; CR, complete response; VGPR, very good partial response; qod, every other day; PFS, progression-free 
survival; TTP time to progression; EFS, event-free survival; OS, overall survival; * by exploratory analysis performed on the 82 patients treated with VMPT induction who received at least 6 months of 










milligrams Maintenance versus no Maintenance 
 EFS or PFS OS 
Attal et al. [32] 597 400 
3-year EFS 
52 vs 37% (P<0.009) 
4-year OS 
87 vs 75% (P<0.04) 




64 vs 43% (P<0.001) 
8-year OS 
57 vs 44% (P=0.09) 




43 vs 22 months 
(P<0.001) 
Median OS 
73 vs 60 months (P=0.77) 
Morgan et al. 
[47,48] 
820 50 
Median PFS (HSCT) 
30 vs 23 months 
(P=0.003) 
3 year OS 
75 vs 80% (P=0.26) 






42 vs 23% (P<0.001) 
3-year OS 
86 vs 75% (P=0.004) 





3 year PFS 
49 vs 43% (P=0.08) 
3 year OS 
80 vs 81% (P=0.817) 





2 year PFS 
64 vs 30% (P=0.002) 
2 year OS 
85 vs 70%  (P=0.27) 





4 year PFS 
32 vs 14% (P<0.0001) 
4 year OS 
68 vs 60 (P=0.18) 
# This cohort was part of a larger 1910 patient study examining other non-transplant therapies. *This cohort was part of a larger 710 patient study examining allogeneic and autologous HSCT. 
Abbreviations:  EFS: Event-free survival; OS: Overall Survival; PFS: Progression-Free Survival  Adapted with permission from McCarthy PL. Part I: the role of maintenance therapy in patients with multiple 
myeloma undergoing autologous hematopoietic stem cell transplantation.  J Natl Compr Canc Netw. 2013 Jan 1;11(1):35-42. 
 









Maintenance versus no Maintenance 
 EFS or PFS OS 




46 vs 27months (P<0.001) 
Median followup 34 m 
85 vs 77% (P=0.028) 
3-year PFS rate 
66% (95% CI, 59 to 73) 
vs 
39% (95% CI, 33 to 48) 
3 year OS rate 
88 % (95% CI, 84 to 93) 
vs 
80 % (95% CI, 74 to 86)  
EFS 
43 vs 27 months (P<0.001) 
 
McCarthy et al [61]  
 Median followup 48 m 
80 vs 70% (P=0.008) 
Attal et al [58] 614 10 
PFS 
41 vs 23 months (P<0.001) 
Median followup 45 m 
74 vs 76% (P=0.7) 
4 year PFS 
43 vs 22% (P<0.001) 
4 year OS 
73 vs75% (NS) 
 
EFS 
40 vs 23 months (P<0.001) 
 
Attal et al [62]  
5 year PFS 
42% vs 18% (P<0.001) 
Median followup 70 m 
5 year OS  
68 vs 67% (NS) 




10 (3 of 4 
weeks 
monthly) 
Landmark Analysis Median 
PFS (combining NIT and IT 
groups) 
42 vs 18 months(P <0.001) 
4 year OS (combining NIT and 
IT groups)  
80 versus 62% (P=0.01) 





10: days 1 
to 21 of 28 




3 year PFS (combining NIT 
and IT groups) 
RP: 60% vs 38% for R alone 
(P=0.003) 
31 month median followup 
(combining NIT and IT groups) 
3 year OS (NIT and IT)  
ND 
EFS: Event-free survival includes deaths, progressions and second cancers; IT: Intensive Therapy; NIT: Non-intensive therapy; ND: No difference, NS: Not significant; OS: Overall Survival; P: Prednisone, 
PFS: Progression-Free Survival, R: Lenalidomide. Adapted with permission from McCarthy PL. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous 




Table 4. Differences between CALGB 100104 and IFM 05 02 
Comparisons CALGB 10010457 IFM 2005-0258 
Induction Thal- or Len-based (74%) VAD (52%) and VD (44%)  
Pre-AHSCT Consolidation None DCEP (25%) 
Number of AHSCT One One (79%), Two (21%) 
Post-AHSCT Consolidation 
before randomization 
None Len: 25 mg daily, 3 of 4 wks for 2 cycles pre-day 
~100 
Median F/Up at un-blinding 18 months 33 months 
Median F/Up from randomization 46 months 64 months 
Cytogenetic stratification Not available More high risk in len arm 
Dosing schedule 10 mg (5 to 15 mg) 10 mg (5-15 mg) 
Time from first patient enrolled 90 months 74 months 
Placebo patients crossed over to  
lenalidomide at un-blinding 
Yes (86 of 128 non-
progressing patients) 
No cross over 
Second primary malignancies 3 fold increase 2.6 fold increase 
Increase in AML/MDS Yes No 
Increase in ALL/HL No Yes 
Maintenance Stopped No Yes at a median of 2 years (range 1 to 3) 
OS after progression* No difference between arms Worse for len than for placebo 
AHSCT: autologous hematopoietic stem cell transplant; ALL/HL: acute lymphocytic leukemia/hodgkin lymphoma; AML/MDS: acute myeloid leukemia/myelodysplastic syndrome; DCEP: 
dexamethasone/cyclophosphamide/etoposide/cisplatin; Len: Lenalidomide; Thal: Thalidomide; VAD: vincristine/doxorubicin/dexamethasone; VD: bortezomib/dexamethasone; * Preliminary analysis 
Adapted with permission from McCarthy PL. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.  J Natl Compr Canc 




Table 5. Bortezomib and Zoledronate Maintenance after Autologous Hematopoietic Stem Cell Transplantation 










Morgan et al 
[53]  
1111 (IT) 
8  (NIT) 
Zoledronate: 4 mg IV 
every 3-4 wks or 
Clodronate 1600 mg 
orally daily  
IT Median PFS 
25 vs 25 months 
 
Median OS for IT patients 
Not reached vs 62.5 months 
HR, 0·84 (95% CI, 0·68–1·03) 
P=0·0854 
   
 Median OS for all patients 
50 vs 45.5 months 





Bortezomib: 1.3 mg/m2IV 
every 2 weeks for 2 years 
or Thalidomide 50 mg 
daily 
Median PFS 
35 vs 28 months 
(P=0.002)  
Median follow-up 41 months 
OS (MV analysis) 




  Landmark analysis for 
those without progression 
at 1 yr  





61 vs 55% 
P=0.07 
Rosiñol et al. 
[76] 
386 Bortezomib 1.3 mg/m2IV 
on days 1, 4, 8, and 11 
every 3 months with 
thalidomide100 mg per 
day orally or thalidomide 
100 mg per day orally 
alone or Interferon alfa (3 
million units SC 3 times 
weekly 
2 year PFS at a median 
follow-up of 24 months 
78 vs 63 vs 49% 
P=0.01 
OS not significantly different 
SC: Subcutaneous; IT: Intensive Therapy; IV: Intravenous; NIT: Non-intensive therapy; MV: Multi-variate; OS: Overall Survival; PFS: Progression-Free Survival  Adapted with permission from McCarthy PL. 
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.  J Natl Compr Canc Netw. 2013 Jan 1;11(1):35-42. 
